Merck, Inc.
๐ต๐ญPhilippines
SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)
Phase 1
Completed
- Conditions
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 59
- Registration Number
- NCT00002960
Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 741
- Registration Number
- NCT00087516
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
Phase 1
Completed
- Conditions
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT00087451
- Locations
- ๐บ๐ธ
The Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, United States
๐บ๐ธBrain Tumor Institute, The Cleveland Clinic, Cleveland, Ohio, United States
๐บ๐ธM.D. Anderson Cancer Center, Houston, Texas, United States
Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2004-07-05
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 353
- Registration Number
- NCT00086502
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-07-05
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 701
- Registration Number
- NCT00086515
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-06-28
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00086125
- Locations
- ๐บ๐ธ
University of Chicago Hospitals, Section of Hematology/Oncology, Chicago, Illinois, United States
๐บ๐ธThe Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment
Phase 2
Terminated
- Conditions
- First Posted Date
- 2004-06-07
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 23
- Registration Number
- NCT00083967
- Locations
- ๐บ๐ธ
Retina Assocites of Cleveland, Inc., Cleveland, Ohio, United States
๐บ๐ธCleveland Clinical Foundation, Cleveland, Ohio, United States
๐บ๐ธRetina Vitreous Associates Medical Group, Los Angeles, California, United States
Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00083343
MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-05-13
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00082537
Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-05-13
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00082524
ยฉ Copyright 2024. All Rights Reserved by MedPath